72 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Aug 2030
Next term end
36
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Aug 2030 · Medium confidence
Also notable
Ends Apr 2038 · Medium confidence
Also notable
Ends Mar 2036 · High confidence
Methods and Compositions for Preventing or Treating Ophthalmic Conditions
US 9,023,807
The most cited patent in this portfolio, cited by 44 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Crystalline Salt Forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
US 11,773,136
Cited by 7 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2038.
Processes for Preparing Pharmaceutically Relevant Peptides
US 10,633,415
Cited by 8 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Peptide Therapeutics and Methods for Using Same (US 10,293,020) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 2 fees due Dec 13 to 18, 2026 · next Dec 13
- 3 fees due Apr 3 to 24, 2027 · next Apr 3
- 1 fee due Jul 7, 2027The maintenance fee for Methods for the Regulation of Matrix Metalloproteinase Expression (US 10,525,098) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 2 fees due Sep 3 to 19, 2027 · next Sep 3
- 3 fees due Oct 2 to 28, 2027 · next Oct 2
- 1 fee due Nov 12, 2027The maintenance fee for Methods and Compositions for the Treatment of Neuropathy and Hyperalgesia (US 10,646,539) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 36 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Preventing or Treating Ophthalmic Conditions | 6 in force | to Aug 2030 |
| Methods and Compositions for the Prevention or Treatment of Barth Syndrome | 5 in force | to Jul 2034 |
| Methods and Compositions for the Prevention and Treatment Neuropathy | 4 in force | to Jul 2033 |
| Crystalline Dipeptides Useful in the Synthesis of Elamipretide | 3 in force | to Mar 2039 |
| Crystalline Salt Forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | 3 in force | to Apr 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,470,784 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · High confidence | In force | High confidence | |
| US 9,023,807 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · Medium confidence | In force | Medium confidence | |
| US 9,549,963 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · Medium confidence | In force | Medium confidence | |
| US 10,188,692 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · Medium confidence | In force | Medium confidence | |
| US 11,612,633 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · High confidence | In force | High confidence | |
| US 11,944,662 | Methods and Compositions for Preventing or Treating Ophthalmic Conditions In force · Medium confidence | In force | Medium confidence | |
| US 8,697,657 | Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides In force · High confidence | In force | High confidence | |
| US 9,561,258 | Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides In force · High confidence | In force | High confidence | |
| US 10,702,577 | Combination Therapies Using Cyclosporine and Aromatic Cationic Peptides In force · Medium confidence | In force | Medium confidence | |
| US 9,345,738 | Methods for the Prevention or Treatment of No-Reflow Following Ischemia/Reperfusion Injury In force · High confidence | In force | High confidence |
Also on record, not counted in the 72: 1 patent in force now held by others · 47 applications pending · 59 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.